FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293207416> ?p ?o ?g. }

• W4293207416 endingPage "921" @default.
• W4293207416 startingPage "917" @default.
• W4293207416 abstract "Infection from the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seems to be less severe in general population in comparison with the previous variants of concern.1Villanego F. Vigara L.A. Alonso M. et al.Trends in COVID-19 outcomes in kidney transplant recipients during the period of omicron variant predominance.Transplantation. 2022; 106: e304-e305Crossref PubMed Scopus (8) Google Scholar However, in kidney transplant recipients (KTRs), Omicron continues to be a considerable threat2Gueguen J. Colosio C. Del Bello A. et al.Early administration of anti–SARS-CoV-2 monoclonal antibodies prevents severe COVID-19 in kidney transplant patients.Kidney Int Rep. 2022; 7: 1241-1247Abstract Full Text Full Text PDF PubMed Scopus (19) Google Scholar due to immunosuppression status and blunt response to vaccination.3Cucchiari D. Egri N. Bodro M. et al.Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients.Am J Transplant. 2021; 21: 2727-2739Crossref PubMed Scopus (167) Google Scholar Clinical trials with remdesivir have demonstrated improved time to recovery in patients on oxygen with coronavirus disease 2019 (COVID-19).4Beigel J.H. Tomashek K.M. Dodd L.E. et al.Remdesivir for the treatment of Covid-19—final report.N Engl J Med. 2020; 383: 1813-1826Crossref PubMed Scopus (4445) Google Scholar In Spain, it was approved in September 2020 for the treatment of COVID-19 in patients with pneumonia, respiratory failure, and less than 8 days since symptoms’ onset. Then, in consideration of the Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting (PINETREE), patients with mild symptomatology and comorbidities were also considered to receive treatment with remdesivir because of its safety profile and the lower risk of hospitalization or death than placebo.5Gottlieb R.L. Vaca C.E. Paredes R. et al.Early remdesivir to prevent progression to severe Covid-19 in outpatients.N Engl J Med. 2022; 386: 305-315Crossref PubMed Scopus (517) Google Scholar Taking into consideration these data, the protocol of our institution (Hospital Clínic, Barcelona, Spain) was changed in November 2021 in order to include all patients with comorbidities (including solid-organ transplantation) to receive remdesivir, independent of the disease severity. The choice of administering remdesivir was also independent of kidney function, considering the different reports of safety in patients with estimated glomerular filtration rate (eGFR) <30 ml/min and/or acute kidney injury.6Buxeda A. Arias-Cabrales C. Pérez-Sáez M.J. et al.Use and safety of remdesivir in kidney transplant recipients with COVID-19.Kidney Int Rep. 2021; 6: 2305-2315Abstract Full Text Full Text PDF PubMed Scopus (16) Google Scholar,7Pettit N.N. Pisano J. Nguyen C.T. et al.Remdesivir use in the setting of severe renal impairment: a theoretical concern or real risk?.Clin Infect Dis. 2021; 73: e3990-e3995Crossref PubMed Scopus (31) Google Scholar All patients who were asymptomatic and/or did not require hospitalization for the severity of COVID-19 were offered to receive remdesivir either at their home through the hospital-at-home (HaH) unit if they were living in the hospital area or by conventional hospitalization. We conducted a retrospective cohort study on KTRs who contracted COVID-19 between November 1, 2021, and February 28, 2022. We assessed the impact of remdesivir on the primary outcome of severe COVID-19, defined as the need of high-flux nasal cannula, noninvasive mechanical ventilation, orotracheal intubation, or death at 30 days after symptoms’ onset. During this time frame, the Omicron variant in Spain was dominant,1Villanego F. Vigara L.A. Alonso M. et al.Trends in COVID-19 outcomes in kidney transplant recipients during the period of omicron variant predominance.Transplantation. 2022; 106: e304-e305Crossref PubMed Scopus (8) Google Scholar and 98 patients followed up in our renal transplant unit developed COVID-19, of whom 57 (58.1%) received remdesivir and 41 (41.9%) did not. The latter category of patients included (i) patients who presented with disease onset >10 days or high–cycle threshold (CT) cycles >30, or both (n = 26); (ii) patients who were hospitalized in other hospitals with different protocols (n = 4); or (iii) patients who rejected hospitalization for living outside the hospital reference area (n = 11). Remdesivir was administered in a single dose of 200 mg, followed by 2 or 4 more daily doses of 100 mg, without renal function adjustment. A total of 5 patients (8.8%) received 3 doses, of whom 2 (40%) were asymptomatic. A total of 50 patients (87.7%) received 5 doses, of whom 46 (92%) were symptomatic. There were 2 isolated cases of patients who received 4 and 7 doses according to the severity of symptoms and the evolution of viral load. Median time between symptoms’ start and administration of the first dose of the drug was 5 days (range, 3–8.5 days). Of the 57 patients who received remdesivir, 44 (77.2%) received it within the first week after symptoms’ start, whereas the remaining 13 (22.8%) received it after. In asymptomatic patients, doses of mycophenolic acid and/or mammalian target of rapamycin inhibitors were decreased. In symptomatic patients with pneumonia, mycophenolic acid and/or mammalian target of rapamycin inhibitors were withdrawn. In patients with significant symptomatology and/or need for oxygen therapy, also calcineurin inhibitors were withdrawn and immunosuppression was maintained with methylprednisolone or equivalent at a dose of at least 0.5 mg/kg/d. Patients’ characteristics are listed in Table 1. No major differences were observed with regard to baseline characteristics, chronic kidney disease and/or transplantation history, immunosuppression, and vaccination status between patients taking remdesivir or not. Almost all patients (84.6%) were vaccinated with at least 2 doses of an mRNA vaccine, the majority of them (71.4%) with the mRNA-1273 (Moderna) vaccine, whereas the other 13.2% with the BNT162b2 (Pfizer) vaccine. No patient received prophylactic monoclonal antibodies such as tixagevimab/cilgavimab (AZD7442, Evusheld; AstraZeneca).Table 1Baseline characteristics of the studied populationTotal population (n = 98)Not remdesivir (n = 41)Remdesivir (n = 57)P valueAge, yr (mean ± SD)58.0 ± 16.355.7 ± 17.359.7 ± 15.40.371Sex (% males)52 (53.1)22 (53.7)30 (52.6)1Ethnicity, n (%)0.425• Caucasian91 (92.9)39 (95.1)52 (91.2)• Hispanic4 (4.1)1 (2.4)3 (5.3)• Asian2 (2.0)—2 (3.5)• African1 (1.0)1 (2.4)—Diabetes (% yes)29 (29.6)9 (22.0)20 (35.1)0.184Body mass index, kg/m2 (mean ± SD)26.0 ± 4.926.7 ± 5.425.4 ± 4.6Current smoker (% yes)7 (7.2)3 (7.5)4 (7.0)1Hypertension (% yes)83 (84.7)34 (82.9)49 (86.0)0.779Ischemic heart disease (% yes)14 (14.3)6 (14.6)8 (14.0)1Baseline eGFR, ml/min (mean ± SD)40.5 ± 20.444.1 ± 21.937.8 ± 19.1• eGFR < 30 ml/min (% of patients)35 (35.7)13 (31.7)22 (38.6)0.527Dialysis vintage, mo, median [IQR]12 [0–35]14 [0–23]12 [0–36]0.310Time since transplantation, mo, median [IQR]92 [31–162]125 [29–164]73 [32–159]0.301Type of transplant, n (%)1• Kidney91 (92.8)38 (92.5)53 (93.0)• SPKT7 (7.2)3 (7.5)4 (7.0)Previous transplant (% yes)29 (29.6)10 (24.4)19 (33.3)0.477Baseline immunosuppression, n (%)0.810• TAC + MPA66 (67.3)27 (65.9)39 (68.4)• TAC + mTORi18 (18.4)8 (19.5)10 (17.5)• Corticosteroids (% yes)83 (84.7)32 (78.0)51 (89.5)0.212 • Dose (mean ± SD)5.3 ± 4.74.7 ± 5.45.7 ± 4.2• Other14 (14.3)6 (14.4)8 (14.0)Previous COVID-19 (% yes)7 (7.1)3 (7.3)4 (7.0)1mRNA vaccination (≥2 doses) (% yes)88 (89.8)35 (85.4)53 (93.0)0.452• 0 dose1 (1.1)0 (0)1 (1.7)• 1 dose2 (2.0)2 (4.9)0 (0)• 2 doses15 (15.3)4 (9.8)11 (19.3)• 3 doses70 (71.4)28 (68.3)42 (73.7)• 4 doses3 (3.1)3 (7.3)0 (0)• Unknown7 (7.1)4 (9.8)3 (5.3)Rejection during the last 6 months (% yes)5 (5.1)4 (9.8)1 (1.8)0.076COVID-19, coronavirus disease 2019; eGFR, estimated glomerular filtration rate; IQR, interquartile range; MPA, mycophenolic acid; mTORi, mammalian target of rapamycin inhibitors; SPKT, simultaneous pancreas-kidney transplantation; TAC, tacrolimus. Open table in a new tab COVID-19, coronavirus disease 2019; eGFR, estimated glomerular filtration rate; IQR, interquartile range; MPA, mycophenolic acid; mTORi, mammalian target of rapamycin inhibitors; SPKT, simultaneous pancreas-kidney transplantation; TAC, tacrolimus. Regarding COVID-19 presentation clinical course, no significant differences were observed in terms of pneumonia, need of oxygen, and use of other drugs, including dexamethasone, tocilizumab, and baricitinib. A total of 13 of 98 (13.3%) patients were asymptomatic, 7 of whom received remdesivir and 6 did not. None of them developed severe COVID-19. Five cases developed COVID-19 during an unrelated hospitalization and all received remdesivir. At the time of receiving remdesivir, 12 patients (21.1%) were asymptomatic, 29 (50.9%) had mild COVID-19, 12 (21.1%) had moderate COVID-19, and 4 (7.0%) had severe COVID-19. Of the total number of patients who started with severe COVID-19 and received remdesivir,4Beigel J.H. Tomashek K.M. Dodd L.E. et al.Remdesivir for the treatment of Covid-19—final report.N Engl J Med. 2020; 383: 1813-1826Crossref PubMed Scopus (4445) Google Scholar only 1 patient died. A total of 15 patients (26.3%) received remdesivir at their place of residence through the HaH unit, the majority of them (86.7%) being symptomatic; 2 of them (13.3%) were diagnosed with pneumonia on chest X-ray and 1 (6.7%) required oxygen. In 4 cases, patients were transferred from the emergency department after a short stay of a median (interquartile range) of 1 day (1–2 days), whereas in all the other 11 cases, HaH admission was direct from the outpatient department. Fifteen patients developed severe COVID-19, defined as the need of high-flux nasal cannula, noninvasive mechanical ventilation, orotracheal intubation, or death (Table 2). In patients who received remdesivir during the first week after symptoms’ start (n = 44), progression to severe COVID-19 or death was observed in 9.1% of cases. On the other hand, in patients who did not receive remdesivir or received it more than 1 week after symptoms’ onset (n = 54), the primary outcome occurred in 20.4% of cases. At univariate logistic analysis (Supplementary Table S1), the factor that was most associated with the development of severe COVID-19 was the presence of pneumonia on chest X-ray at presentation with an odds ratio (OR) (95% confidence interval [CI]) of 54.35 (6.62–442.80, P < 0.001). The patient’s age was also associated with the primary outcome, with an OR (95% CI) of 1.05 (1.00–1.09) per year increase (P = 0.026). The use of remdesivir was not associated with the outcome (OR [95% CI]: 1.53 [0.48–4.87], P = 0.470). However, when taking into account its early use (≤7 days since symptoms’ onset), it was associated with protection from the outcome in hospitalized patients, either including patients admitted to HaH (OR [95% CI]: 0.13 [0.03–0.47], P = 0.002) or not (OR [95% CI]: 0.15 [0.03–0.64], P = 0.010). In the time-to-event analysis, early use of remdesivir was still associated with a more favorable outcome in comparison with late or null administration only in hospitalized patients (Figure 1).Table 2Clinical course and outcomes after administration or not of remdesivir of the studied populationTotal population (n = 98)Not remdesivir (n = 41)Remdesivir (n = 57)P valueClinical course (%)0.308• Asymptomatic (% yes)13 (13.3)7 (17.1)6 (10.5)• Mild COVID-19 (% yes)51 (52.0)24 (58.6)27 (47.4)• Moderate COVID-19 (% yes)19 (19.4)5 (12.2)14 (24.6)• Severe COVID-19 (% yes)15 (15.3)5 (12.2)10 (17.5)Hospitalization (including HaH) (% yes)69 (70.4)12 (29.3)57 (100.0)<0.001Hospitalization (excluding HaH) (% yes)54 (55.1)12 (29.3)42 (73.7)0.001Time from onset COVID-19 symptoms to onset remdesivir, d——5 (3–8.5)Other COVID-19 treatment, n (%)• Dexamethasone (% yes)25 (25.5)9 (22.0)16 (28.1)0.639• Tocilizumab15 (15.3)5 (12.2)10 (17.5)0.575• Baricitinib7 (7.2)1 (2.5)6 (10.5)0.234Need of oxygen during hospital stay (% yes)29 (29.6)9 (22.0)20 (35.1)0.184Pneumonia on chest X-ray (% yes)31 (31.6)10 (24.4)21 (36.8)0.271Severe disease or death (% yes)15 (15.3)5 (12.2)10 (17.5)0.575• Death (% yes)7 (7.1)2 (4.9)5 (8.8)0.460Outcomes at 30 d after symptoms’ onset, n (%)0.380• Discharged87 (88.8)38 (92.9)49 (84.0)• Still hospitalized5 (5.1)1 (2.4)4 (7.0)• Death6 (6.1)2 (4.9)4 (7.0)COVID-19, coronavirus disease 2019; HaH, hospital-at-home. Open table in a new tab COVID-19, coronavirus disease 2019; HaH, hospital-at-home. In patients receiving remdesivir, kidney function did not worsen at hospital discharge (baseline eGFR [mean ± SD]: 39.0 ± 18.7 ml/min, at discharge [mean ± SD]: 41.8 ± 20.9 ml/min, P = 0.189), also in patients with baseline eGFR <30 ml/min (baseline 20.4 ± 4.5 ml/min, at discharge 28.4 ± 17.3 ml/min, P = 0.078). Three patients in the remdesivir group started chronic hemodialysis during their hospital stay, as their kidney function was already deteriorated before admission (baseline eGFR [median (IQR)]: 8 [7–13] ml/min). Two of them started hemodialysis before receiving the drug and 1 after receiving it. Patients who received remdesivir in the hospital had a median (interquartile range) length of stay of 8 (5–17) days, not significantly different from the control group: 14 (6–19) days, P = 0.477. Considering also patients who were transferred to the HaH unit, the total length of stay (HaH + hospital) lowered to 7 (5–13.75) days in patients taking remdesivir, not significantly different from patients not taking it (P = 0.226). In conclusion, in our cohort of patients who received remdesivir for COVID-19, we observed protection from severe disease only in hospitalized patients with early administration of the drug (≤7 days within symptoms’ onset). This is coherent with data in general population that indicate that the drug is effective if given properly during the viremic phase of the disease.5Gottlieb R.L. Vaca C.E. Paredes R. et al.Early remdesivir to prevent progression to severe Covid-19 in outpatients.N Engl J Med. 2022; 386: 305-315Crossref PubMed Scopus (517) Google Scholar In terms of safety, our data also suggest that it can be administered safely in KTRs also with eGFR <30 ml/min. The limitations of our study include its retrospective nature and a small sample size in order to obtain more solid conclusions. Patients not treated with remdesivir were not hospitalized in more than two-thirds of cases, probably reflecting less severe cases of COVID-19. Conversely, patients who received remdesivir had to be admitted to receive the medication, which increased the number of admissions in this group. This may highlight an inherent selection bias for which patients at lower risk of complications from COVID-19 did not receive remdesivir. This is also highlighted by the observation that in the whole population, the time of remdesivir initiation was not associated with the primary outcome. In terms of severe disease, another bias could be a lower threshold for receiving remdesivir in sicker patients, linked to a higher likelihood of developing severe disease in this group. However, in both cases, this could have theoretically skewed the results in favor of the not-remdesivir group and not the contrary. On the other hand, the control group was well matched in terms of all the other baseline parameters and developed COVID-19 during the same epidemic wave. This adds value to the present work, because so far reports have been focused only on the safety of remdesivir in KTRs and no control groups have been reported. Other strategies that may be employed against COVID-19 in KTRs include passive immunization with monoclonal antibodies active against the Omicron variant (sotrovimab)2Gueguen J. Colosio C. Del Bello A. et al.Early administration of anti–SARS-CoV-2 monoclonal antibodies prevents severe COVID-19 in kidney transplant patients.Kidney Int Rep. 2022; 7: 1241-1247Abstract Full Text Full Text PDF PubMed Scopus (19) Google Scholar and further boosts of immunization with mRNA or heterologous vaccines. All the authors declared no competing interests. The data that support the findings of this study are available on reasonable request addressed to the corresponding author. Download .docx (.01 MB) Help with docx files Supplementary File (Word)" @default.
• W4293207416 created "2022-08-27" @default.
• W4293207416 creator A5000311687 @default.
• W4293207416 creator A5012540380 @default.
• W4293207416 creator A5022084784 @default.
• W4293207416 creator A5038016111 @default.
• W4293207416 creator A5038633110 @default.
• W4293207416 creator A5047232429 @default.
• W4293207416 creator A5053833967 @default.
• W4293207416 creator A5055535924 @default.
• W4293207416 creator A5060748574 @default.
• W4293207416 creator A5070317803 @default.
• W4293207416 creator A5071822857 @default.
• W4293207416 creator A5082894673 @default.
• W4293207416 creator A5087851609 @default.
• W4293207416 creator A5088119944 @default.
• W4293207416 creator A5088594199 @default.
• W4293207416 date "2022-10-01" @default.
• W4293207416 modified "2023-10-18" @default.
• W4293207416 title "Use of remdesivir in kidney transplant recipients with SARS-CoV-2 Omicron infection" @default.
• W4293207416 cites W3027630905 @default.
• W4293207416 cites W3112400346 @default.
• W4293207416 cites W3165003372 @default.
• W4293207416 cites W3182985230 @default.
• W4293207416 cites W4200206478 @default.
• W4293207416 cites W4220920928 @default.
• W4293207416 cites W4225793022 @default.
• W4293207416 doi "https://doi.org/10.1016/j.kint.2022.08.001" @default.
• W4293207416 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35964801" @default.
• W4293207416 hasPublicationYear "2022" @default.
• W4293207416 type Work @default.
• W4293207416 citedByCount "6" @default.
• W4293207416 countsByYear W42932074162022 @default.
• W4293207416 countsByYear W42932074162023 @default.
• W4293207416 crossrefType "journal-article" @default.
• W4293207416 hasAuthorship W4293207416A5000311687 @default.
• W4293207416 hasAuthorship W4293207416A5012540380 @default.
• W4293207416 hasAuthorship W4293207416A5022084784 @default.
• W4293207416 hasAuthorship W4293207416A5038016111 @default.
• W4293207416 hasAuthorship W4293207416A5038633110 @default.
• W4293207416 hasAuthorship W4293207416A5047232429 @default.
• W4293207416 hasAuthorship W4293207416A5053833967 @default.
• W4293207416 hasAuthorship W4293207416A5055535924 @default.
• W4293207416 hasAuthorship W4293207416A5060748574 @default.
• W4293207416 hasAuthorship W4293207416A5070317803 @default.
• W4293207416 hasAuthorship W4293207416A5071822857 @default.
• W4293207416 hasAuthorship W4293207416A5082894673 @default.
• W4293207416 hasAuthorship W4293207416A5087851609 @default.
• W4293207416 hasAuthorship W4293207416A5088119944 @default.
• W4293207416 hasAuthorship W4293207416A5088594199 @default.
• W4293207416 hasBestOaLocation W42932074161 @default.
• W4293207416 hasConcept C116675565 @default.
• W4293207416 hasConcept C126322002 @default.
• W4293207416 hasConcept C142724271 @default.
• W4293207416 hasConcept C159047783 @default.
• W4293207416 hasConcept C2778137277 @default.
• W4293207416 hasConcept C2779134260 @default.
• W4293207416 hasConcept C2780091579 @default.
• W4293207416 hasConcept C2780303639 @default.
• W4293207416 hasConcept C2994498544 @default.
• W4293207416 hasConcept C3006700255 @default.
• W4293207416 hasConcept C3007834351 @default.
• W4293207416 hasConcept C3008058167 @default.
• W4293207416 hasConcept C524204448 @default.
• W4293207416 hasConcept C71924100 @default.
• W4293207416 hasConceptScore W4293207416C116675565 @default.
• W4293207416 hasConceptScore W4293207416C126322002 @default.
• W4293207416 hasConceptScore W4293207416C142724271 @default.
• W4293207416 hasConceptScore W4293207416C159047783 @default.
• W4293207416 hasConceptScore W4293207416C2778137277 @default.
• W4293207416 hasConceptScore W4293207416C2779134260 @default.
• W4293207416 hasConceptScore W4293207416C2780091579 @default.
• W4293207416 hasConceptScore W4293207416C2780303639 @default.
• W4293207416 hasConceptScore W4293207416C2994498544 @default.
• W4293207416 hasConceptScore W4293207416C3006700255 @default.
• W4293207416 hasConceptScore W4293207416C3007834351 @default.
• W4293207416 hasConceptScore W4293207416C3008058167 @default.
• W4293207416 hasConceptScore W4293207416C524204448 @default.
• W4293207416 hasConceptScore W4293207416C71924100 @default.
• W4293207416 hasIssue "4" @default.
• W4293207416 hasLocation W42932074161 @default.
• W4293207416 hasLocation W42932074162 @default.
• W4293207416 hasLocation W42932074163 @default.
• W4293207416 hasOpenAccess W4293207416 @default.
• W4293207416 hasPrimaryLocation W42932074161 @default.
• W4293207416 hasRelatedWork W3005417802 @default.
• W4293207416 hasRelatedWork W3007868867 @default.
• W4293207416 hasRelatedWork W3009669391 @default.
• W4293207416 hasRelatedWork W3020699490 @default.
• W4293207416 hasRelatedWork W3036314732 @default.
• W4293207416 hasRelatedWork W3043486364 @default.
• W4293207416 hasRelatedWork W3084498529 @default.
• W4293207416 hasRelatedWork W3090578646 @default.
• W4293207416 hasRelatedWork W4210401150 @default.
• W4293207416 hasRelatedWork W3127156785 @default.
• W4293207416 hasVolume "102" @default.
• W4293207416 isParatext "false" @default.
• W4293207416 isRetracted "false" @default.

• next